anchor links
2024
-
New C2H Report: Ropeginterferon Alfa-2b (Besremi)
-
New C2H Report: Ensitrelvir (Xocova)
-
New C2H Report: Tirzepatide (Mounjaro)
-
New C2H Report: Tezepelumab (Tezspire)
-
New C2H Report: Deucravacitinib (Sotyktu)
-
New C2H Report: Molnupiravir (Lagevrio)
-
New C2H Report: Finerenone (Kerendia)
2023
-
New C2H Report: Efgartigimod Alfa (Vyvgart)
-
New C2H Report: Valbenazine (Dysval)
-
New C2H Report: Bimekizumab (Bimzelx)
-
New C2H Report: Andexanet alfa (Ondexxya)
-
New C2H Report: Clazosentan (Pivlaz)
-
New C2H Report: Selpercatinib (Retevmo)
-
New C2H Report: Gefapixant (Lyfnua)
-
New C2H Report: Expedium Verse Fenestrated Screw system
-
New C2H Report: Micra AV (Micra transcatheter pacing system)
-
New C2H Report: Enfortumab vedotin (Padcev)
-
New C2H Report: Teduglutide (Revestive)
-
New C2H Report: Galcanezumab (Emgality)
-
New C2H Reports: Daratumumab Vorhyaluronidase Alfa (Darzquro) and Polatuzumab Vedotin (Polivy)
-
New C2H Reports: Amikacin sulfate (Arikayce) and Remdesivir (Veklury)
2022
-
New guideline for cost-effectiveness evaluation in English
-
New C2H Report: Trastuzumab deruxtecan (Enhertu)
2021
-
New C2H Report: Vortioxetine (Trintellix) and Ivabradine (Coralan)
-
New C2H Report: Ravulizumab (Ultomiris)
-
The first reports of the cost-effectiveness evaluation were released.
2020
2019
-
Guidelines for analysis of cost-effectiveness evaluation published
-
Materials from the International Symposium have been posted
-
Our new website is open
-
C2H holds international symposium